中文 English
简体 English
返回

News

Enterprise dynamics Media focus
News
Home
/
News
/
Media focus

Synthetic biology: basic chemical engineering, life renewal and leading the future (report receiving)

Synthetic biology is the result of a high degree of integration of multiple disciplines Synthetic biology gathers and integrates many disciplines such as life science, engineering and information science. It has broad application prospects in many fields such as natural product synthesis, chemical industry, bioenergy, biomedicine and so on. The industrialization of production products by means of synthetic biology mainly includes five important links: strain transformation, metabolic regulation, separation and purification, polymerization process and application development. Synthetic biology can realize the quantitative control of products, and its core lies in the precise regulation of strain transformation process and synthetic pathway by using genetic engineering. Many factors have promoted the rapid development of synthetic biology, and the industry has entered the landing period of application transformation The accumulation of basic research, breakthroughs in key enabling technologies and new and high financing rate of the industry jointly promote the synthetic biology industry to enter the market entry period. The global synthetic biology company can be divided into basic layer and application layer. The basic layer company grasps the technology of object design and automation platform, DNA and RNA synthesis or software design. The core of the application layer company is to apply synthetic biology technology to the development and marketization of products such as medical care, industrial chemicals and biofuels. China's synthetic biology industry is at an early stage. The production enterprises are distributed in the basic layer and the application layer, mostly concentrated in the basic layer, and some technologies have global leading advantages.   Synthetic biology has production advantages in green chemical manufacturing 60% of the material inputs in the global economy can be produced by biological means. Different from the traditional microbial fermentation production mode, the green manufacturing of chemicals is to re synthesize a new artificial biological system to convert raw materials into products at a high rate. Synthetic biology has three production advantages in the field of chemical manufacturing: (1) the synthetic biological manufacturing route is milder, more energy-saving and low-carbon than the traditional petrochemical route; (2) Some biological products have significant cost advantages; (3) some synthetic biological manufacturing has advanced technology and has more advantages in product quality.   The barrier of synthetic biology industrialization mainly lies in solving the problem of realizing large-scale production technology For enterprises that synthesize products by biological method, the process from laboratory scientific research results to product commercialization focuses on the realization of large-scale production process, and whether the large-scale production process can be realized mainly depends on the transformation efficiency of front-end bacteria and the amplification effect of back-end process. (1) The design of high-performance strains and better synthetic ways will improve the conversion rate, production efficiency and yield scale of synthetic biological products; (2) The research and development of efficient and low-cost separation and purification technology can not only realize the important link of product industrialization, but also an important technical bottleneck to determine the large-scale industrialization practice of biological manufacturing. (3) Choosing a product with long-term market space and value is also very important for enterprises engaged in the industrialization of synthetic biological manufacturing.   The application of synthetic biology in chemical industry will usher in a broad space for development According to the statistics of CB insights and Biospace, in 2020, the global synthetic biology market scale will be US $6.1 billion, and the industry CAGR will be 16.15% from 2017 to 2020. CB insights predicts that the industry scale is expected to increase to US $18.9 billion by 2024; From the perspective of downstream application market structure, medical health and industrial chemicals are two important application fields of synthetic biology. At present, many chemical enterprises have realized the production of chemicals and fuels by biological manufacturing. Chemical manufacturing and bioenergy product development based on synthetic biology will help to break the resource and environmental bottleneck of economic development and build a new green industrialization road of sustainable development. In the next 10-20 years, synthetic biology will have a great impact on the traditional industrial production mode by improving the existing fermentation process, developing new biological pathways for the production of existing materials and chemicals, and producing new materials and chemicals. 1、 Overview of synthetic biology Source: Che
More
27
2022-02

American Unicorn: a pioneer in DNA synthesis biology, twist Bioscience

Date: : 2022-02--27
Scientific research in the field of life sciences has been "out of the circle" frequently recently. At the end of 2021, a new achievement successfully attracted people's attention - in December 2021, the news of "Southeast University 'writing' its motto into DNA" was crazily swiped on major platforms. This achievement was published in the international journal science advances. Professor Liu Hong's team from the school of Bioscience and medical engineering of Southeast University and the State Key Laboratory of Bioelectronics reported a fully integrated DNA data storage system, which realized the integration of data writing and reading on a single electrode through the synthesis of DNA molecules on the electrode surface and in-situ sequencing, and successfully put the school motto "rest in the highest excellence!" It is stored on the electrode surface in the form of DNA molecules and read out. This is the original "Romance" of engineering. This "brain opening" research result has laid a foundation for the development of high-throughput integrated automated DNA storage system in the future. With the advent of the era of big data, the global data generation is increasing exponentially, and the data storage system based on DNA molecules is considered to be a feasible solution to the future "data crisis", and it is also a good example for BT to solve it problems. For the future track of DNA data storage, entrepreneurs with keen sense of smell have long paid attention to its commercial value, and twist Bioscience (NASDAQ: twst), a leader in DNA synthesis, is one of them. DNA based data storage was already part of Twist's plan before its launch in 2018. In November 2020, twist announced that it had formed an alliance with Illumina, a global gene sequencing giant, Western Digital, a leader in data storage industry, and Microsoft to jointly promote the development of DNA data storage and create a comprehensive industry roadmap. In May 2021, twist announced that it had successfully synthesized 200 base pair oligonucleotides on its DNA chip developed for data storage. It is reported that the size of these silicon-based chips is only 1 µ M. Dr. Emily lepraust, CEO and co-founder of the company, said at that time that this is a considerable achievement and the longest DNA synthesized on the smallest silicon-based chip in history. However, the company believes that in order to truly realize commercialization, the size of the chip needs to be reduced to 150nm, so there are still many key technologies to break through. 1.1 # technical platform Twist's DNA synthesis platform highly miniaturizes the traditional chemical DNA synthesis reaction, reduces the reaction volume by 1 million times, and improves the throughput by 1000 times, so that 9600 genes can be completely synthesized on a single silicon chip; In the same physical space, the traditional synthesis method can only synthesize one gene on a 96 well plate. At the same time, the high-throughput DNA synthesis technology platform greatly reduces the use of reagents. Compared with the traditional oligonucleotide synthesis, the reagent consumption can be reduced by 99.8%, and the synthetic products are almost zero waste in the subsequent assembly process. The chip is combined with the company's proprietary software system, expandable business infrastructure and e-commerce platform to create an integrated technology platform. Compared with peers, twist significantly reduces the cost of DNA synthesis, ensures the quality and accuracy of synthesis, realizes automation and improves throughput. Comparison between traditional 96 well plate DNA synthesis (left) and twist bioscience silicon chip DNA synthesis platform (right) Twist is using its unique technology to manufacture a wide range of products based on synthetic DNA, including synthetic genes, high-throughput sequencing (NGS) preparation tools and antibody libraries for drug development. At the same time, twist is also looking for longer-term opportunities in the digital storage of DNA data and the development of biological products. The company's products have been widely used in health care, industrial chemicals, agriculture, academic research and many other industries. 1.2 existing product line: derived from synthetic biological tools + ngs tools Twist's existing product line is derived from synthetic biology tools and ngs tools, mainly including synthetic biology products, IgG protein, NGS tools, synthetic virus control and infectious disease research tools, drugs and target discovery solutions. Synthetic genes can be used in chemical / material, food / agriculture, treatment, diagnosis, product development of data storage and academic research. Synthetic genes mainly include two kinds: one is cloned gene, also known as DNA carrier, with a length of up to 5000 base pairs; The other is a non cloned gene fragment, which can be put into the vector with a length of up to 1800 base pairs, and the error rate is as l
Read more Read more
18
2020-11

Kangmu pharmaceutical new R & D center put into use

Date: : 2020-11--18
Pay attention to R & D investment and increase development momentum 　Recently, the new office building of nearly 4000 square meters and the R & D center of 1300 square meters of Zhejiang Kangmu Pharmaceutical Co., Ltd. have been put into use, further improving the R & D capacity and office environment of the company's API. "The new office building is conducive to the exchange of technology and technology and the introduction of talents." Yao yu'e, director of Human Resources Department of Zhejiang Kangmu Pharmaceutical Co., Ltd., introduced that now the company's new R & D center has been put into use, and four new products have entered the stage of small-scale test and pilot test. It is expected that the output value will increase by 15% year-on-year this year. It is understood that Kangmu pharmaceutical attached great importance to R & D at the beginning of its establishment and adhered to "scientific and technological innovation". Now it has three research institutes, namely API Research Institute, preparation research institute and Analysis Research Institute. It is a comprehensive modern animal health enterprise integrating the R & D, production and sales of veterinary API and preparation. Among them, chlorfenicol and tilmicosin series APIs are the designated production units of the Ministry of agriculture, and the products are also exported to many countries and regions such as the Americas, the Middle East and Southeast Asia. At present, the company has "Zhejiang agricultural science and technology R & D center" and "Shaoxing enterprise technology center". With the change of the age structure of farmers, farmers are willing to try new things, and the research and development of new products has become the lifeline of Kangmu pharmaceutical industry. In recent years, the company's R & D investment has increased steadily, especially in the past two years. The R & D investment exceeded 14 million yuan in 2018 and 16 million yuan in 2019. "The importance of R & D is obvious to all, so Kangmu pharmaceutical has always adhered to the independent R & D route." Yao yu'e told reporters that while constantly strengthening the construction of its own R & D system, the company also actively cultivates and introduces technical talents, and focuses on strengthening industry university research cooperation with well-known universities and research institutions to further enhance the company's technical strength. Among them, Kangmu pharmaceutical's new process project with an annual output of 500 tons of florfenicol API has been listed as the "provincial spark project" by the Provincial Department of science and technology, and has been listed in the national torch plan. "Green production technology project of florfenicol to achieve energy conservation and emission reduction" has been listed in the key R & D plan of Zhejiang Province by the Provincial Department of science and technology. At present, Kangmu pharmaceutical has established a good partnership with Zhejiang University, Zhejiang University of technology, Fudan University, Shanghai Sixin Biochemical Technology Co., Ltd., German Leibniz Catalytic Research Institute, China Pharmaceutical University, etc., providing strong technical support for the company's subsequent product development and process optimization. At present, the veterinary medicine industry has a high technical content, which has high requirements for the personnel and equipment of enterprise R & D institutions. Since June, the Ministry of agriculture and animal husbandry has put forward the requirements for the reconstruction of veterinary drug production workshops and the relocation of veterinary drug production enterprises in rural areas, which meet the requirements of the Ministry of agriculture and animal husbandry. "The state pays more and more attention to the safety of veterinary drug products, gradually improves the requirements for product stability, medicinal and ecological safety, and puts forward higher requirements for enterprise safety production and environmental protection." Yuan Qing, technical director of Zhejiang Kangmu Pharmaceutical Co., Ltd., said that recently, the company focused on the technical transformation of wastewater treatment early warning system and workshop automation control system, and also added high-efficiency centrifuges, high-efficiency distillation columns and other equipment, which is believed to provide stronger hardware support for the safe production of enterprises.
Read more Read more
17
2014-06

记浙江康牧药业有限公司副总经理康先禄

Date: : 2014-06--17
"Is it difficult to be a human medicine or a veterinary medicine?" Kang Xianlu, who has transformed from developing "human medicine" to "veterinary medicine", replied that "it is more difficult to make veterinary medicine". Where is the difficulty? "The difficulty is that veterinary drugs can not have the slightest residue, otherwise, people will increase drug resistance after eating animal meat with residual drugs, and the consequences will be 'incurable'.". Kang Xianlu, a graduate student of Zhejiang University, comes from Chongqing. His fate with Kang Mu originated in 2006. That year, he came from Zhejiang Jingxin Pharmaceutical Co., Ltd. to Zhejiang Kangmu Co., Ltd. as deputy general manager and technical director. "From Chongqing to Zhejiang University, and from Xinchang to Shengzhou, and the company's name is Kang Mu. My last name is Kang. It's really a kind of fate." When it comes to Kang Mu, I can always feel a light shining in Kang Xianlu's eyes. Since joining Kangmu, kangxianlu has been committed to the company's new product R & D and technological innovation. He focused on the florfenicol production technology project, devoted himself to the development and research, used the methods of finding a large number of relevant international and domestic scientific and technological information and materials, and adopted a large number of trial production and research means such as small-scale test, pilot test and expansion test. He personally did everything from equipment selection to equipment coefficient and formula coefficient. In less than half a year, the new florfenicol process and technology he studied and tested had a significant breakthrough. In order to shorten the process flow, he also perfectly solved the problems such as solvent replacement. Now the product quality is stable, the production cost is greatly reduced, the environmental pollution is reduced, and obvious economic and social benefits have been achieved. There should be no mistake in the production process, which is Kang Xianlu's requirement for employees. Kang Xianlu always goes to each workshop to have a look at the first thing at work every day. He said that Kangmu's products are mainly chemical synthesis. As the technical manager, he must always master the production dynamics. Even if he hears a slight fluctuation of data in the workshop, it will affect his nerves. "The process of chemical operation is a precise process, and the order of fine to feeding must not be reversed, otherwise the product composition will be changed and the reactor will explode in serious cases." From the laboratory to the production workshop, Kang Xianlu is not only a developer, but also a gatekeeper. From the feeding sequence, feeding speed and amplification effect, he and his colleagues calculated and demonstrated again and again to accumulate experience in practice. "I came from a technical background. My task is to constantly carry out technological innovation, reduce the labor intensity of workers and ensure safe production." He said that chemical enterprises are different from other enterprises. Once an accident occurs, the consequences are unimaginable. He is most gratified that Kangmu has not had a safety accident in more than eight years. Today, the annual output of flufenicol API for animals independently developed by Kang Xianlu can reach 600 tons. Both sales and technology rank among the top three in China. It has been listed as a provincial spark project by the Provincial Department of science and technology and a national torch plan project by the Ministry of science and technology. Now, he also reduces COD emissions in the production process by developing new solvents. During this time, Kang Xianlu was busy with the company's FDA certification. "Now the FDA (US Food and Drug Administration) certification application has been submitted. FDA can be called the most authoritative and strictest pharmaceutical regulatory audit organization in the world. Getting FDA certification is equivalent to getting a pass to enter the European market." Thinking that FDA certification can lead the company to a broader market, he smiled with expectation. "As a technician in a veterinary medicine enterprise, I have the responsibility to do a good job in veterinary medicine, which is also my mission." When it comes to the future, Kang Xianlu said that he will continue this fate better and be a new Shengzhou person who contributes to the economic development of Shengzhou.
Read more Read more
Página anterior
1

E-mail：ad@zjkmpharm.com

08:15-17:00

Add：

No. 358, chengluo industrial district, Shengzhou City, Zhejiang Province

Tel：0575-83120595

Search
康牧动保

No. 358, chengluo industrial district, Shengzhou City, Zhejiang Province

official account
Copyright © Zhejiang Kangmu Animal Health Co., Ltd. 浙ICP备2021026151号-1 Powered by:300.cn SEO
OA system >